Ajinomoto Bio-Pharma Services Japan California

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

View original content:https://www.prnewswire.co.uk/news-releases/ajinomoto-and-exelixis-enter-into-a-license-agreement-to-discover-and-develop-novel-antibody-drug-conjugates-for-the-treatment-of-cancer-301717126.html